A Study of GC203 TIL in Advanced Malignant Solid Tumors

Trial Details

NCT ID

NCT06375187

Phase

PHASE1

Sponsor

Shanghai Juncell Therapeutics

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Engineering Tumor Infiltrating Lymphocytes

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.
• 2\. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced metastatic solid tumors with clear pathological dia…
• 4\. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue \> 400mm3, and the lesio…
• 6\. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.